Skip to main content

Advertisement

SpringerLink
Log in

Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

When considering BRCA1/2 genetic testing for diagnosis of hereditary breast and ovarian cancer (HBOC), family history (FH) of breast and ovarian cancer is commonly considered. However, FH of other HBOC-related cancers, such as prostate, pancreatic, and skin cancer (malignant melanoma), is often overlooked.

Methods

Among 945 patients who received genetic testing of BRCA1/2 at our hospital between October 2010 and September 2021, we compared the FH of 123 patients diagnosed with HBOC and 669 other patients who had breast cancer and had a documented FH. This study focused on the FH of HBOC-related cancers such as breast, ovarian, prostate, pancreatic, and skin cancer, as well as colorectal, gastric, liver, lung, and uterine cancers, which are common among Japanese, and other cancers.

Results

FH of prostate, pancreatic, and skin cancer was significantly higher in the BRCA2 pathogenic variant (PV) cases than in the wild-type (WT) cases. The mean number of family members are as follows: BRCA1 PV/ BRCA2 PV/ WT; prostate cancer: 0.05/ 0.34/ 0.09 (P < 0.0001, Kruskal–Wallis multiple comparisons test), pancreatic cancer: 0.13/ 0.21/ 0.10 (P = 0.01637), and skin cancer: 0.03/ 0.07/ 0.01 (P = 0.00129), respectively.

Conclusions

When considering BRCA1/2 genetic testing, FH of prostate, pancreatic, and skin cancers may also be examined as HBOC-related cancers to provide testing for patients who would benefit from it. However, further studies for the association between skin cancer and HBOC will be required because it has not been reported in Japan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: updated evidence report and systematic review for the us preventive services task force. JAMA. 2019;322:666–85.

    Article  Google Scholar 

  2. Pilarski R. The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.

  3. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, et al. Role of genetic testing for inherited prostate cancer risk: philadelphia prostate cancer consensus conference 2017. J Clin Oncol. 2018;36:414–24.

    Article  CAS  Google Scholar 

  4. Silvestri V, Leslie G, Barnes DR, Group C, Agnarsson BA, Aittomaki K, et al. Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). JAMA Oncol. 2020; 6: 1218–30.

  5. Mizukami K, Iwasaki Y, Kawakami E, Hirata M, Kamatani Y, Matsuda K, et al. Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes. EBioMedicine. 2020;60: 103033.

    Article  Google Scholar 

  6. Toussi A, Mans N, Welborn J, Kiuru M. Germline mutations predisposing to melanoma. J Cutan Pathol. 2020;47:606–16.

    Article  Google Scholar 

  7. Ginsburg OM, Kim-Sing C, Foulkes WD, Ghadirian P, Lynch HT, Sun P, et al. BRCA1 and BRCA2 families and the risk of skin cancer. Fam Cancer. 2010;9:489–93.

    Article  Google Scholar 

  8. Gumaste PV, Penn LA, Cymerman RM, Kirchhoff T, Polsky D, McLellan B. Skin cancer risk in BRCA1/2 mutation carriers. Br J Dermatol. 2015;172:1498–506.

    Article  CAS  Google Scholar 

  9. Leachman SA, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P, et al. Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev. 2017;36:77–90.

    Article  CAS  Google Scholar 

  10. Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res. 2019;11:2321–37.

    Article  Google Scholar 

  11. Angeli D, Salvi S, Tedaldi G. Genetic predisposition to breast and ovarian cancers: how many and which genes to test? Int J Mol Sci. 2020; 21.

  12. Hereditary Cancer Syndromes and Risk Assessment: Acog Committee Opinion, Number 793. Obstet Gynecol 2019; 134(6): e143–e9.

  13. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transp. 2013;48:452–8.

    Article  CAS  Google Scholar 

  14. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–90.

    Article  CAS  Google Scholar 

  15. James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA, et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol. 2006;24:707–15.

    Article  CAS  Google Scholar 

  16. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20:2701–12.

    Article  CAS  Google Scholar 

  17. Kang E, Park SK, Lee JW, Kim Z, Noh WC, Jung Y, et al. KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients. J Hum Genet. 2016;61:365–71.

    Article  CAS  Google Scholar 

  18. Junejo NN, AlKhateeb SS. BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update. Saudi Med J. 2020; 41: 9–17.

  19. Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 2015;17:569–77.

    Article  CAS  Google Scholar 

  20. Pilarski R. The role of BRCA testing in hereditary pancreatic and prostate cancer families. Am Soc Clin Oncol Educ Book. 2019;39:79–86.

    Article  Google Scholar 

  21. Momozawa Y, Iwasaki Y, Parsons MT, Kamatani Y, Takahashi A, Tamura C, et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun. 2018;9:4083.

    Article  Google Scholar 

  22. Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol. 2020;77:24–35.

    Article  CAS  Google Scholar 

  23. Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017; 2017.

  24. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310–6.

    Article  Google Scholar 

  25. Johannsson O, Loman N, Möller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer. 1999;35:1248–57.

    Article  CAS  Google Scholar 

  26. Moran A, O’Hara C, Khan S, Shack L, Woodward E, Maher ER, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer. 2012;11:235–42.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the certified genetic counselor Serina Sasaki, MMS (Genome medical center, National Hospital Organization Hokkaido Cancer Center) for support with data collection.

Author information

Authors and Affiliations

  1. Genome Medical Center, National Hospital Organization Hokkaido Cancer Center, 2-3-54, Kikusui 4, Shiroishi-ku, Sapporo, 003-0804, Japan

    Yuko Minoura & Masato Takahashi

  2. Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, 2-3-54, Kikusui 4, Shiroishi-ku, Sapporo, 003-0804, Japan

    Masato Takahashi, Hideki Maeda, Sayuri Kuwahara, Hanae Tachikawa, Mitsugu Yamamoto, Nobumoto Tomioka & Kenichi Watanabe

  3. Department of Medical Genetics and Genomics, Sapporo Medical University School of Medicine, S1 W17, Chuo-ku, Sapporo, 060-8556, Japan

    Yuko Minoura & Akihiro Sakurai

Authors
  1. Yuko Minoura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masato Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideki Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sayuri Kuwahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hanae Tachikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mitsugu Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobumoto Tomioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenichi Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akihiro Sakurai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masato Takahashi.

Ethics declarations

Conflict of interest

Masato Takahashi and Akihiro Sakurai received honorarium (lecture fee) from AstraZeneca K.K.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Minoura, Y., Takahashi, M., Maeda, H. et al. Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer. Breast Cancer 29, 808–813 (2022). https://doi.org/10.1007/s12282-022-01360-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-022-01360-2

Keywords

Search

Navigation